IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 297 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,378,400 | -47.9% | 920,000 | -3.7% | 0.71% | -47.2% |
| Q1 2024 | $14,153,100 | +55.9% | 955,000 | -14.5% | 1.34% | +47.9% |
| Q4 2023 | $9,079,730 | +110.1% | 1,116,818 | +17.6% | 0.91% | +94.6% |
| Q3 2023 | $4,322,500 | -27.8% | 950,000 | +11.8% | 0.47% | -26.1% |
| Q2 2023 | $5,984,000 | +41.8% | 850,000 | +23.9% | 0.63% | +36.3% |
| Q1 2023 | $4,219,946 | -23.6% | 686,170 | -20.6% | 0.46% | -19.6% |
| Q4 2022 | $5,523,375 | +16.0% | 864,378 | +69.5% | 0.58% | +15.4% |
| Q3 2022 | $4,763,000 | -18.6% | 510,000 | -3.8% | 0.50% | -25.0% |
| Q2 2022 | $5,851,000 | -26.0% | 530,000 | +11.6% | 0.66% | -14.7% |
| Q1 2022 | $7,909,000 | -32.1% | 475,000 | -20.8% | 0.78% | +0.6% |
| Q4 2021 | $11,652,000 | +47.7% | 600,000 | +87.5% | 0.78% | +39.9% |
| Q3 2021 | $7,891,000 | +1.1% | 320,000 | +6.7% | 0.55% | +4.5% |
| Q2 2021 | $7,806,000 | -16.4% | 300,000 | +1.7% | 0.53% | -18.6% |
| Q1 2021 | $9,340,000 | -37.1% | 295,000 | -7.8% | 0.65% | -46.2% |
| Q4 2020 | $14,848,000 | +32.7% | 320,000 | -5.9% | 1.21% | +21.7% |
| Q3 2020 | $11,193,000 | +19.9% | 340,000 | 0.0% | 1.00% | -1.3% |
| Q2 2020 | $9,333,000 | -14.6% | 340,000 | -6.8% | 1.01% | -34.2% |
| Q1 2020 | $10,926,000 | -16.9% | 365,000 | -23.2% | 1.53% | +6.2% |
| Q4 2019 | $13,148,000 | +38.9% | 475,000 | -8.7% | 1.44% | +21.5% |
| Q3 2019 | $9,464,000 | -48.6% | 520,000 | -30.7% | 1.19% | -41.5% |
| Q2 2019 | $18,407,000 | +120.0% | 750,700 | -14.7% | 2.03% | +107.4% |
| Q1 2019 | $8,365,000 | -21.6% | 879,600 | -27.0% | 0.98% | -19.8% |
| Q4 2018 | $10,669,000 | -26.5% | 1,205,495 | -6.6% | 1.22% | -16.2% |
| Q3 2018 | $14,518,000 | +33.8% | 1,290,495 | +52.3% | 1.46% | +31.1% |
| Q2 2018 | $10,848,000 | -32.0% | 847,476 | -10.2% | 1.11% | -43.6% |
| Q1 2018 | $15,957,000 | +111.3% | 944,185 | 0.0% | 1.97% | +92.7% |
| Q4 2017 | $7,553,000 | +37.0% | 944,185 | +32.8% | 1.02% | +45.0% |
| Q3 2017 | $5,512,000 | +15.4% | 711,163 | +9.4% | 0.70% | +2.6% |
| Q2 2017 | $4,778,000 | – | 650,000 | – | 0.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MHR Fund Management | 19,997,103 | $90,986,819 | 11.15% |
| MPM BioImpact LLC | 3,287,397 | $14,957,656 | 3.99% |
| Perceptive Advisors | 11,962,938 | $54,431,367 | 1.82% |
| CM Management, LLC | 200,000 | $910,000 | 0.97% |
| Velan Capital Investment Management LP | 250,000 | $1,137,500 | 0.92% |
| Opaleye Management Inc. | 610,000 | $2,775,500 | 0.90% |
| Boxer Capital, LLC | 3,705,133 | $16,858,355 | 0.90% |
| SECTORAL ASSET MANAGEMENT INC | 985,000 | $4,481,750 | 0.87% |
| Parametrica Management Ltd | 95,400 | $434,070 | 0.73% |
| 683 Capital Management, LLC | 2,050,000 | $9,327,501 | 0.72% |